Targeting non-alcoholic fatty liver disease through 11-βHSD1 inhibition
Lancet Diabetes Endocrinol
.
2014 May;2(5):354-6.
doi: 10.1016/S2213-8587(14)70028-2.
Epub 2014 Feb 17.
Author
Vlad Ratziu
1
Affiliation
1
Université Pierre et Marie Curie, Hospital Pitié Salpêtrière, Paris 75013, France; INSERM U938, Paris, France. Electronic address: vlad.ratziu@upmc.fr.
PMID:
24795242
DOI:
10.1016/S2213-8587(14)70028-2
No abstract available
Publication types
Comment
MeSH terms
11-beta-Hydroxysteroid Dehydrogenase Type 1 / antagonists & inhibitors*
Female
Humans
Male
Non-alcoholic Fatty Liver Disease / drug therapy*
Substances
11-beta-Hydroxysteroid Dehydrogenase Type 1